Latest Intelligence on Pharmaceuticals and Healthcare in India

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

HIV drugs: India clears the path

Published By Datamonitor
12 Sep 2001
ResearchWire
ResearchWire

Trauma devices: internal devices to grow fastest in India

Published By Datamonitor
03 May 2002
CommentWire
CommentWire

Novo Nordisk/Dr Reddy's: cancer fears freeze diabetes drug

Novo Nordisk has suspended human trials of ragaglitazar, after discovering tumors in rodents that had been fed the experimental drug. The possible loss of ragaglitazar, which had been forecast peak annual sales of $1.78 billion, is Novo Nordisk's third setback this year. It also hits the drug's originator Dr Reddy's hard.

Published By Datamonitor
23 Jul 2002
CommentWire
CommentWire

Cipla: lobbying for more generics in South Africa

Generics maker Cipla is trying to cut a deal to supply South African mining firm Anglo American with HIV drugs. Employer provision of HIV medicine is gaining popularity in South Africa, and last year's court case created the opportunity for the government to license generic versions of patented drugs. However, it has so far been reluctant to use this power.

Published By Datamonitor
20 Aug 2002
CommentWire
CommentWire

HIV patents: no solution - yet

While the WTO has not yet made a breakthrough on the issue of patent-free HIV drugs for developing economies, something must be done to alleviate the human and economic cost of the HIV epidemic. Western pharma companies will inevitably lose out - the only question is how well their profit maintenance strategies can cushion the blow.

Published By Datamonitor
22 Oct 2002
CommentWire
CommentWire

Pfizer: a triumph of the heart

Pfizer's share price has surged on news that the company has successfully defended two key Lipitor patents, deferring the threat of generic competition until 2011. This will enable Pfizer to proceed with plans to switch Lipitor patients to its controversial phase III torcetrapib and atorvastatin combination product before Lipitor is affected by generic competition, safeguarding its revenue stream.

Published By Datamonitor
20 Dec 2005
CommentWire
CommentWire

Ranbaxy: considers bid for Merck's generics unit

As the first company to express an interest in buying Merck's generics business, Ranbaxy has recognized that the acquisition would make it the world's third largest global generics player behind Teva and Novartis' Sandoz. However, the Indian-based company is likely to face competition from not only rival generics companies but also Big Pharma groups keen to diversify into the high-growth market.

Published By Datamonitor
10 Jan 2007
Expert View
Expert View

Indian pharmaceutical companies: innovative HIV drug reformulations

The FDA has tentatively approved new HIV drug co-formulations combining lamivudine, zidovudine (both originally developed by GSK) and nevirapine (by Boehringer Ingelheim) for use under the PEPFAR program. India's Cipla and Aurobindo, the manufacturers, have showed a remarkable creativity that may eventually pay off in high-price markets like the US and Europe.

Published By Datamonitor
08 Feb 2007
Expert View
Expert View

Big Pharma rushing for foothold in emerging markets despite challenges

Faced with dwindling growth rates in the US and Europe, drug companies are turning their attention towards emerging pharmaceutical markets where recent economic booms have fuelled double-digit growth. However, although the patient potential of these countries is enormous, foreign pharmaceutical companies are currently tapping into only a fraction of the market.

Published By Datamonitor
13 Mar 2008
CommentWire
CommentWire

Merck & Co: enters into R&D partnership with Ranbaxy

US-based Merck and India's biggest pharmaceutical company Ranbaxy have entered into an agreement to develop antibacterial and antifungal drugs. The deal highlights the trend of big pharmaceutical companies turning to India and China for R&D. As well as allowing Merck to develop its infectious disease portfolio, the agreement should provide valuable synergies for both companies.

Published By Datamonitor
13 May 2008

« | 1 | 2 | » »|

No help is available.